We found four secretory proteins (AKR1B10, annexin A2P2, ZNF468, and CD24) and we showed through our own cohort study that plasma AKR1B10 could be a clinically applicable biomarker for NASH (AUROC 0.834) and for advanced fibrosis (AUROC 0.914) at a cutoff level (≥1078.2 pg/mL). This evidence concerns the gene CD24 and metabolic dysfunction-associated steatohepatitis.